Hydroxyurea with concomitant radiotherapy for locally advanced head and neck cancer
Vokes, E.E.; Haraf, D.J.; Panje, W.R.; Schilsky, R.L.; Weichselbaum, R.R.
Seminars in Oncology 19(3 Suppl 9: 53-58
1992
ISSN/ISBN: 0093-7754 PMID: 1641658 Document Number: 399930
Hydroxyurea is an active single agent in squamous cell cancer of the head and neck. It has been used clinically, most frequently as a radiation-enhancing agent with concomitant radiotherapy. Pilot trials testing hydroxyurea in this setting reported encouraging results. Two randomized trials have been conducted with inconclusive results, possibly relating to study cohort size and short period of follow-up. More recently, hydroxyurea has been investigated with 5-fluorouracil and concomitant radiotherapy. A sound theoretic rationale can be made for this approach and data derived from a phase I/II study are presented. These support the further investigation of this regimen.